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and Arner, 2001). In this context it is 
fascinating that protein damage caused 
by H2O2-mediated oxidative stress is 
repaired by a system that is upregulated 
at the transcriptional level by this ROS.
However, the presence of epidermal 
MSRA is not sufficient to recover oxidized 
methionines, due to the production of 
both the (R) and the (S) diastereomers of 
methionine sulfoxide by H2O2-mediated 
oxidation. It therefore was not surprising 
to find highly expressed and functional 
MSRB in the epidermal compartment in 
situ as well as in keratinocytes, as shown 
in Figure 1 (K. Rübsam, ongoing medical 
thesis, University of Hamburg). Hence, it 
can be concluded that proteins and pep-
tides damaged as a result of the oxidation 
of methionines in their sequences can be 
totally salvaged by MSRA and MSRB. In 
this context it is noteworthy that both 
TR and the MSRs express cytosolic and 
mitochondrial membrane-integrated iso-
forms, thus maintaining mitochondrial 
as well as cytosolic stability (Hansel et 
al., 2002; Nordberg and Arner, 2001; 
Schallreuter and Wood, 2001).
The importance of epidermal TR/T for 
redox homeostasis
As early as in 1989 it was recognized that 
human epidermal keratinocytes express 
high levels of both cytosolic and mem-
brane-integrated TR. This enzyme is sub-
ject to allosteric inhibition by calcium 
due to a single EF-hands binding site (for 
review see Schallreuter and Wood, 2001). 
Therefore, epidermal calcium homeosta-
sis not only controls differentiation, but 
clearly also controls redox balance. The 
selenoenzyme TR, in addition to being 
the electron donor for both MSRs, this 
selenoenzyme has a very broad speci-
ficity, reducing disulfide bridges, H2O2, 
organoperoxides, vitamin K, and alloxan 
(Nordberg and Arner, 2001).
In summary, the discovery of the 
MSRs in the skin adds yet another 
important role to the epidermal anti-
oxidant repair machinery. Moreover, the 
presence and function of these reduc-
tases imply a functional TR/T system. 
Whether the reductases themselves 
may also be targets for oxidative stress 
remains to be determined.
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"Out, Damned Spot!"
Richard A. Spritz1
Mice transgenic for the Kit Val620Ala mutation, which in humans has been asso-
ciated with progressive piebaldism, exhibit dominant white spotting but show 
no evidence of progressive depigmentation. These results are consistent with 
the previous hypothesis that progressive piebaldism might result from digen-
ic inheritance, of the KITV620A mutation that causes piebaldism and a second, 
unknown locus that causes progressive depigmentation.
Journal of Investigative Dermatology (2006) 126, 949–951. doi:10.1038/sj.jid.5700220
Lady Macbeth’s anguished lament 
speaks to some of the most puzzling 
conundrums in investigative derma-
tology. The white-spotting disorder 
piebaldism, because of its visually 
striking patches of white skin (leuko-
derma) and hair (poliosis), was known 
to the ancient Romans and is thought 
to be the first genetic disorder to have 
been recognized to exhibit autosomal 
dominant inheritance (Morgan, 1786). 
We have learned a lot over the cen-
turies. We now know that the leuko-
dermal patches result from an almost 
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|Skin aging is also associated with a decreased capacity to 
neutralize ROS
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total lack of melanocytes from the 
involved regions. We now know that 
human piebaldism, and the homolo-
gous murine mutant “dominant white 
spotting” (W), result from loss-of-func-
tion and dominant-negative missense 
mutations in the KIT gene, and that 
there is a general correlation between 
genotype and severity of the resultant 
clinical phenotype (Spritz, 1994). We 
now know that KIT encodes the cell 
surface transmembrane tyrosine kinase 
receptor for KIT ligand (mast-cell 
growth factor; stem-cell factor; steel 
factor), and that KIT-dependent signal-
ing plays key roles in melanogenesis, 
gametogenesis, and early stages of 
hematopoiesis. Nevertheless, the most 
obvious clinical questions remain 
unanswered. Why is developmen-
tal lack of melanocytes in piebaldism 
so localized, resulting in white spots 
rather than diffuse hypopigmentation? 
Why do the white spots preferentially 
involve the forehead, ventral chest and 
trunk, backs of the elbows, and fronts 
of the knees? Why are the congenital 
leukodermal patches of piebaldism so 
stable over a patient’s life, neither fill-
ing in nor growing larger, whereas the 
acquired white spots of vitiligo may 
wax and wane? And why are the white 
spots of piebaldism utterly resistant to 
medical treatment, whereas those of 
vitiligo may fill in after ultraviolet ther-
apy and immunotherapy?
Although the leukodermal patches 
of piebaldism typically lack mela-
nocytes, they frequently contain 
hyperpigmented islands, abnormally 
pigmented macules, and freckles, all 
of which contain apparently normal 
melanocytes. Furthermore, the leuko-
dermal patches often exhibit marginal 
hyperpigmentation, compared with 
the surrounding skin, which appears 
essentially normal. In human piebald-
ism, and in mice with “dominant white 
spotting” (W), the leukodermal patches 
are remarkably stable, usually being 
evident at birth and changing little over 
the course of patients’ lives, although 
limited filling in has been reported in 
some milder cases of piebaldism (Davis 
and Verdol, 1976). Together, these 
phenomena suggest that deficient KIT-
dependent signaling results in a prima-
ry defect of migration of neural crest 
melanoblasts to the skin during embry-
ologic development and, furthermore, 
interferes with local migration of skin 
melanoblasts and melanocytes during 
postnatal life.
Recently, Richards and co-workers 
(2001) reported a mother and daugh-
ter with the remarkable phenotype 
of progressive piebaldism, the result 
of a novel amino acid substitution, 
Val620Ala (V620A), located in a highly 
conserved region of the KIT intracellular 
tyrosine kinase domain. In both mother 
and daughter, congenital skin and hair 
depigmentation progressed from infan-
cy through at least mid-childhood, ulti-
mately resulting in a relatively severe 
piebald phenotype. The biological basis 
for the highly atypical progressive clini-
cal course in this family was not stud-
ied but would seem to imply reduced 
survival of skin melanocytes and self-
renewing melanoblasts, in addition to 
defective melanoblast migration dur-
ing development. Interestingly, several 
other family members had a tendency 
to localized hair graying but did not 
carry the KIT mutation. Accordingly, the 
authors speculated that progressive pie-
baldism in this family might result from 
digenic co-inheritance of the KITV620A 
mutation and an unknown dominant-
acting unlinked mutation responsible 
for progressive hair graying.
In this issue, Tosaki et al. describe 
detailed investigation of the biology 
of the KitV620A substitution in trans-
genic mice, aiming to create an ani-
mal model for progressive piebaldism. 
Another Kit tyrosine kinase domain 
substitution, D790N, had been shown 
to act as a dominant-negative in trans-
genic mice (Ray et al., 1991); this 
suggested that KitV620A might behave 
similarly, providing an animal model 
in which to study the biology of pro-
gressive melanocyte loss. The authors 
accordingly engineered the V620A 
substitution in mouse Kit complemen-
tary DNA, prepared four independent 
transgenic mouse lines, and carefully 
assessed the resultant phenotypes. 
Surprisingly, whereas all four trans-
genic lines exhibited dominant white 
spotting and reduction of mast-cell 
numbers consistent with the W-mutant 
phenotype, none of the lines showed 
any evidence of postnatal progression 
of the pigmentary phenotype. Thus, the 
KitV620A transgenic mice exhibit typi-
cal dominant white spotting but fail to 
model the most interesting aspect of 
the homologous human mutant pheno-
type, progressive depigmentation.
Tosaki and colleagues (2006) offer 
several hypotheses as to why the KitV620A 
transgenic mice do not manifest pro-
gressive depigmentation. They point out 
that KIT-dependent signaling is required 
both for developmental migration of 
melanoblasts to the skin and also for 
melanoblast/melanocyte maintenance 
and survival (Nishikawa et al., 1991; 
Okura et al., 1995; Kunisada et al., 
2001; Botchkareva et al., 2001), and 
they imply that KITV620A might affect the 
latter more in humans than in mice. 
However, this would require that the 
KIT-V620A polypeptide exert a stable 
dysfunctional effect, in addition to or 
instead of acting as a straightforward 
dominant-negative. Perhaps more likely 
is the original hypothesis of Richards 
et al. (2001), that the family with pro-
gressive piebaldism segregated two 
unlinked mutations: KITV620A, causing 
typical dominant piebaldism, and a 
mutation in a second, unknown locus, 
causing progressive hair graying. Very 
recently, hair graying has indeed been 
linked to incomplete maintenance of 
self-renewing melanoblasts, in which 
Pax3 and Mitf seem to play key roles 
(Steingrimsson et al., 2005). Although 
Richards and co-workers (2001) found 
no mutations of MITF in their origi-
nal family, digenic inheritance involv-
ing KIT and some other locus remains 
an attractive hypothesis to account for 
progressive piebaldism in this family. 
Nevertheless, a full understanding of 
this phenomenon may await identifica-
tion of genes specifically involved in 
hair graying in humans, and so, for now, 
atypical progressive piebaldism associ-
ated with KITV620A must be added to the 
list of conundrums, rather than to the 
list of puzzles solved.
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Lipid Rafts: Membrane Triage Centers
Xiao-qi Wang1 and Amy S. Paller1
Both biochemical and live cell imaging studies suggest the existence of lipid 
rafts, specialized membrane microdomains that promote interaction among sig-
naling molecules. Although their composition is still poorly understood, these 
highly dynamic domains are enriched in cholesterol, sphingolipids, and particu-
lar groups of proteins. The mechanism(s) by which trafficking into or out of lipid 
rafts affects signaling remains unclear.
Journal of Investigative Dermatology (2006) 126, 951–953. doi:10.1038/sj.jid.5700282
Lipid rafts are compartmentalized 
membrane microdomains into which 
membrane lipids and proteins sort, 
allowing specific interactions that mod-
ulate signal transduction, membrane 
trafficking, cytoskeletal organization 
and motility, polarization, and patho-
gen entry (for reviews, see Rajendran 
and Simons, 2005; Pike, 2005). These 
membrane microdomains are thought 
to result from a tightly ordered lipid 
phase that is enriched in sterols (includ-
ing cholesterol), as well as sphingolip-
ids (including gangliosides) and phos-
pholipids with saturated hydrocarbon 
chains. Although many cell surface 
proteins localize to the liquid disor-
dered regions of the membrane, some 
proteins selectively partition into the 
lipid raft domains. These include gly-
cosylphosphatidylinositol-anchored 
proteins (such as the urokinase-type 
plasminogen activator receptor), myris-
toylated or palmitoylated proteins 
(such as flotillin), doubly acetylated 
proteins (such as Src-family kinases), 
phospholipid-bound proteins (such as 
annexins), and cholesterol-bound trans-
membrane proteins (such as caveolins 
and hedgehog). Membrane microdo-
mains are highly dynamic and possess 
considerable lateral mobility within the 
loosely ordered membrane.
Lipid rafts are defined by their resis-
tance to extraction with nonionic 
detergents and their low density in 
sucrose gradients. Lipid rafts have been 
subdivided into caveolar and non-
caveolar rafts that coexist in distinct 
membrane areas. Caveolar domains 
contain caveolae, stable flask-shaped 
invaginations of the plasma membrane 
that were recognized ultrastructurally 
more than 50 years ago. Caveolae are 
enriched in cholesterol and coated by 
the hairpin-like palmitoylated structural 
protein caveolin-1, which is thought 
to stabilize the invaginated caveolar 
structure. Non-caveolar lipid rafts are 
flat membrane microdomains that are 
also enriched in cholesterol and resis-
tant to detergent extraction but have 
less caveolin-1 than caveolae. Unlike 
caveolar rafts, non-caveolar lipid 
rafts are heterogeneous in lipid and 
protein composition.
Problems associated with the study of 
lipid rafts
In initial studies, membrane com-
ponents were extracted in 1% Triton 
X-100 at 4 °C and divided by centrifuga-
tion in a linear 5%–30% sucrose gradi-
ent. Milder detergents, such as Nonidet 
P-40, octylglucoside, CHAPS, Brij 58, 
and Brij 98, have more recently been 
used to isolate membranes, allowing 
the discovery of several proteins that are 
localized to lipid rafts but excluded by 
their Triton X-100 sensitivity. Rafts have 
also been isolated by detergent-free 
techniques (for example, use of a sodium 
carbonate buffer at alkaline pH or sepa-
ration by serial gradients). The type of 
detergent, the temperature, the cell type, 
and the technique used for extraction 
influence phase behavior and protein 
composition. Thus, recovery of a group 
of lipids and proteins within the same 
fraction of detergent-resistant membrane 
does not, in itself, indicate colocaliza-
tion within the cell membrane.
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